Literature DB >> 6875809

Kinetics of d-tubocurarine disposition and pharmacologic response in rats.

A Morino, K Kitamura, K Katayama, M Kakemi, T Koizumi.   

Abstract

After bolus intravenous dosing of d-tubocurarine (d-TC) to rats, the twitch heights of the tibialis anterior muscle indirectly stimulated were followed, and its decrease was defined as pharmacologic response of d-TC. The relation between dose and response intensity was found to be well described with Hill's equation. According to a theory proposed by Smolen, Hill's equation was also applicable to the biophase d-TC concentration-response relation; the time courses of the relative biophase d-TC concentration indicated linear kinetics with dose levels less than or equal to 0.15 mg/kg and the occurrence of dose-dependent disposition with 0.30 mg/kg. After bolus i.v. dosing of 3H-d-TC, plasma d-TC concentration obeyed a dose-independent two compartment model with doses less than or equal to 0.15 mg/kg, but not with 0.30 mg/kg. This finding matched the above estimated with pharmacologic data. The active metabolite was not found in plasma and urine. The extent of d-TC plasma protein binding was independent of the wide range of plasma levels and its mean (+/- SD) value was 30.5 (+/- 3.8). Plasma d-TC levels and pharmacologic response intensity were well correlated by Hill's equation and a three compartment model (the general two and the biophase compartments) in the dose range less than or equal to 0.15 mg/kg.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6875809     DOI: 10.1007/bf01061767

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  11 in total

1.  THE DISTRIBUTION AND FATE OF D-TUBOCURARINE.

Authors:  E N COHEN; A CORBASCIO; G FLEISCHLI
Journal:  J Pharmacol Exp Ther       Date:  1965-01       Impact factor: 4.030

2.  The routine fitting of kinetic data to models: a mathematical formalism for digital computers.

Authors:  M BERMAN; E SHAHN; M F WEISS
Journal:  Biophys J       Date:  1962-05       Impact factor: 4.033

3.  The elimination of d-tubocurarine in the rat.

Authors:  E F VAN MAANEN
Journal:  J Pharmacol Exp Ther       Date:  1950-11       Impact factor: 4.030

4.  Pharmacodynamics of tubocurarine in humans.

Authors:  L B Wingard; D R Cook
Journal:  Br J Anaesth       Date:  1976-09       Impact factor: 9.166

5.  Theoretical and computational basis for drug bioavailability determinations using pharmacological data. I. General considerations and procedures.

Authors:  V F Smolen
Journal:  J Pharmacokinet Biopharm       Date:  1976-08

6.  The dependence of pancuronium- and d-tubocurarine-induced neuromuscular blockades on alveolar concentrations of halothane and forane.

Authors:  R D Miller; W L Way; W M Dolan; W C Stevens; E I Eger
Journal:  Anesthesiology       Date:  1972-12       Impact factor: 7.892

7.  Kinetics of the elimination and neuromuscular blocking effect of d-tubocurarine in man.

Authors:  M Gibaldi; G Levy; W Hayton
Journal:  Anesthesiology       Date:  1972-03       Impact factor: 7.892

8.  A pharmacodynamic model for pancuronium.

Authors:  C J Hull; H B Van Beem; K McLeod; A Sibbald; M J Watson
Journal:  Br J Anaesth       Date:  1978-11       Impact factor: 9.166

9.  Pharmacokinetics and pharmacodynamics of d-tubocurarine during nitrous oxide-narcotic and halothane anesthesia in man.

Authors:  D R Stanski; J Ham; R D Miller; L B Sheiner
Journal:  Anesthesiology       Date:  1979-09       Impact factor: 7.892

10.  Simultaneous modeling of pharmacokinetics and pharmacodynamics: application to d-tubocurarine.

Authors:  L B Sheiner; D R Stanski; S Vozeh; R D Miller; J Ham
Journal:  Clin Pharmacol Ther       Date:  1979-03       Impact factor: 6.875

View more
  1 in total

1.  A novel pharmacokinetic method for analysis of placental transfer of latamoxef in humans.

Authors:  T Yamamoto; J Yasuda; M Kanao; H Okada; T Oguma; H Yamada
Journal:  Clin Pharmacokinet       Date:  1986 Mar-Apr       Impact factor: 6.447

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.